A Phase 3, Randomized Trial Evaluating Avutometinib Plus Defactinib Compared With Investigator’s Choice of Therapy (ICT) in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC): GOG-3097/ENGOT-ov81/NCRI/RAMP 301
A Phase 3, Randomized Trial Evaluating Avutometinib Plus Defactinib Compared With Investigator’s Choice of Therapy (ICT) in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC): GOG-3097/ENGOT-ov81/NCRI/RAMP 301
This website uses cookies to improve the site and user experience. By continuing to browse this site, you agree to accept our use of cookies. For more information, please review our Privacy Policy.
